Tag: eight-weeks
-
AbbVie’s hepatitis C treatment shows promise
(Reuters) – Drugmaker AbbVie Inc said on Friday its experimental fixed-dose combination to treat certain hepatitis C virus patients achieved high sustained viral response (SVR) rates after eight weeks of treatment. The once-daily fixed-dose combination, glecaprevir/pibrentasvir (G/P), was given to HCV patients without cirrhosis and who were new to treatment in three different studies. About…
-
Mosul families squat in squalor between frontline and camps
By John Davison SHAHREZAD, Iraq (Reuters) – At the small mosque in Shahrezad village, piles of human faeces dot the toilets and rubbish is strewn around the garden. Fifty people are crammed into an abandoned and bombed-out home nearby, screening off its rooms with sheets for privacy, two days after fleeing fighting in Mosul for…
-
Expert Views: What will be the impact of Trump presidency on immigration, refugees?
By Ellen Wulfhorst and Sebastien Malo NEW YORK (Thomson Reuters Foundation) – The election of Republican Donald Trump to be the next U.S. president raises questions about the impact his administration could have upon immigrants in the United States and the nation's immigration and refugee policies. During his campaign Trump took a hardline position, proposing…
-
Audi CEO to face renewed VW emissions inquiry: sources
Audi Chief Executive Rupert Stadler will again be questioned by U.S. law firm Jones Day on a reported discovery of a new cheat software device at the luxury car brand, two people familiar with the matter said. Germany's Bild am Sonntag reported a week ago that a U.S. regulator had earlier this year found a…
-
Lilly says new type of pain drug could lessen need for opioids
Eli Lilly and Co on Tuesday said it and partner Pfizer Inc aim to seek approval by 2018 for a new type of pain drug that could be an alternative to opioids for osteoarthritis, chronic back pain and cancer pain. The Indianapolis drugmaker said tanezumab, given by injection every eight weeks, could be a far…
-
Lilly says new type of pain drug could lessen need for opioids
Eli Lilly and Co on Tuesday said it and partner Pfizer Inc aim to seek approval by 2018 for a new type of pain drug that could be an alternative to opioids for osteoarthritis, chronic back pain and cancer pain. The Indianapolis drugmaker said tanezumab, given by injection every eight weeks, could be a far…